Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 154

Sort by

Sort Order Select

Journal Articles

Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)

Blood (2024) 144 (Supplement 1): 406.

https://doi.org/10.1182/blood-2024-206143

Published: 2024

Journal Articles

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Blood (2024) 144 (Supplement 1): 659.

https://doi.org/10.1182/blood-2024-193678

Published: 2024

Journal Articles

Redefining Prognosis in Patients with KIT D816V Positive Advanced Systemic Mastocytosis on KIT Inhibitors

Johannes Luebke, Nicole Naumann, Georgia Metzgeroth, Hans-Peter Horny, Karl Sotlar, Martina Rudelius, Alice Fabarius, Wolf-Karsten Hofmann, Juliana Schwaab, Andreas Reiter

Blood (2024) 144 (Supplement 1): 660.

https://doi.org/10.1182/blood-2024-193760

Published: 2024

Journal Articles

Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting

Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti H. Radia, Johannes Luebke, Priyanka J. Bobbili, Aolin Wang, Saša Dimitrijević, Erin Sullivan, Juliana Schwaab, Ilene A. Galinsky, Cecelia Perkins, Wolfgang R. Sperr, Priya Sriskandarajah, Manasi Mohan, Teshawna Badu, Mei Sheng Duh, Peter Valent, Daniel J. DeAngelo

Blood (2024) 144 (Supplement 1): 1801.

https://doi.org/10.1182/blood-2024-204015

Published: 2024

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Hepatic Involvement in Advanced Systemic Mastocytosis: Clinical and Histopathological Correlates and Future Implications

Isabel Farmer, Anna C Green, Priya Sriskandarajah, Juliana Schwaab, Anton Rets, Deborah Moulton, Hayder KA Hussein, Susan Asirvatham, Tracy I. George, Andreas Reiter, Deepti H. Radia

Blood (2024) 144 (Supplement 1): 6627.

https://doi.org/10.1182/blood-2024-200591

Published: 2024

Journal Articles

CSF3R T618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)

Alessandra Hartke, Julia Klotz, Axel Künstner, Anke Fähnrich, Hauke Busch, Timo Gemoll, Jasmin Osius, Steffen Koschmieder, Tim H. H. Brummendorf, Heike L. Pahl, Florian H. Heidel, Konstanze Döhner, Martin Griesshammer, Andreas Reiter, Justus Duyster, Nikolas C. C. von Bubnoff, Sivahari P. Gorantla

Blood (2024) 144 (Supplement 1): 1348.

https://doi.org/10.1182/blood-2024-202513

Published: 2024

Journal Articles

Disease-Modifying Effects of Avapritinib in Patients with Advanced Systemic Mastocytosis: Improvements in Bone Density

Johannes Luebke, Tracy I. George, Daniel J. DeAngelo, Jason Gotlib, Deepti H. Radia, Michael W. Deininger, Aaron Zakharyan, Joana Caetano-Lopes, Sasa Dimitrijevic, Andreas Reiter

Blood (2024) 144 (Supplement 1): 4544.

https://doi.org/10.1182/blood-2024-193774

Published: 2024

Journal Articles

How I (Diagnose and) Treat Myeloid / Lymphoid Neoplasms with Tyrosine Kinase Gene Fusions

Andreas Reiter, Georgia Metzgeroth, Nicholas C.P. Cross

Blood blood.2023022417.

https://doi.org/10.1182/blood.2023022417

Published: 2024

Journal Articles

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Blood (2024) 143 (11): 1006–1017.

https://doi.org/10.1182/blood.2023020515

Published: 2024

Includes: Supplemental data

Journal Articles

Diagnosis and Outcome of Patients with Idiopathic Hypereosinophilic Syndrome and Cardiac Involvement

Johannes Lübke, Anna Hohneck, Jan Leipe, Nicole Naumann, Alice Fabarius, Wolf-Karsten Hofmann, Georgia Metzgeroth, Theano Papavassilu, Andreas Reiter, Juliana Schwaab

Blood (2023) 142 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2023-187249

Published: 2023

Journal Articles

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Blood (2023) 142 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2023-180945

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

Blood (2023) 142 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2023-178304

Published: 2023

Journal Articles

Predicting the Clinical Course of Treatment with Midostaurin in Patients with Advanced Systemic Mastocytosis

Johannes Lübke, Nicole Naumann, Timo Brand, Hans-Peter Horny, Martina Rudelius, Karl Sotlar, Georgia Metzgeroth, Alice Fabarius, Wolf-Karsten Hofmann, Juliana Schwaab, Andreas Reiter

Blood (2023) 142 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2023-182322

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Blood (2022) 140 (21): 2228–2247.

https://doi.org/10.1182/blood.2022015853

Published: 2022

Includes: Supplemental data

Journal Articles

Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

Frank Stegelmann, Lino L. Teichmann, Florian H. Heidel, Carl C. Crodel, Thomas Ernst, Sebastian Kreil, Andreas Reiter, Sara Otten, Stefanie Schauer, Ruth-Miriam Körber, Kim Kricheldorf, Susanne Isfort, Hartmut Döhner, Tim H. Brümmendorf, Martin Griesshammer, Konstanze Döhner, Steffen Koschmieder

Blood (2022) 140 (Supplement 1): 6874–6876.

https://doi.org/10.1182/blood-2022-165034

Published: 2022

Journal Articles

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Blood (2022) 140 (Supplement 1): 590–593.

https://doi.org/10.1182/blood-2022-158501

Published: 2022

Journal Articles

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2022) 140 (Supplement 1): 1790–1793.

https://doi.org/10.1182/blood-2022-157265

Published: 2022

Journal Articles

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Srdan Verstovsek, Jason Gotlib, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Huiling Zhen, Natalia Oliveira, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 3980–3982.

https://doi.org/10.1182/blood-2022-163099

Published: 2022

Journal Articles

Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study

Deepti H. Radia, Jason Gotlib, Mark W. Drummond, Tracy I. George, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Daniel J. DeAngelo, Andreas Reiter

Blood (2022) 140 (Supplement 1): 1509–1511.

https://doi.org/10.1182/blood-2022-166986

Published: 2022

NARROW

Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Redefining Prognosis in Patients with KIT D816V Positive Advanced Systemic Mastocytosis on KIT Inhibitors

Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Hepatic Involvement in Advanced Systemic Mastocytosis: Clinical and Histopathological Correlates and Future Implications

CSF3R T618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)

Disease-Modifying Effects of Avapritinib in Patients with Advanced Systemic Mastocytosis: Improvements in Bone Density

How I (Diagnose and) Treat Myeloid / Lymphoid Neoplasms with Tyrosine Kinase Gene Fusions

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Diagnosis and Outcome of Patients with Idiopathic Hypereosinophilic Syndrome and Cardiac Involvement

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

Predicting the Clinical Course of Treatment with Midostaurin in Patients with Advanced Systemic Mastocytosis

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only